Q2 EPS Forecast for Elanco Animal Health Reduced by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst B. Vazquez now forecasts that the company will earn $0.22 per share for the quarter, down from their previous forecast of $0.27. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.91 EPS.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share.

ELAN has been the subject of several other reports. Stifel Nicolaus dropped their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Morgan Stanley dropped their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Trading Up 2.4 %

Shares of ELAN stock opened at $11.19 on Thursday. The stock has a market capitalization of $5.53 billion, a PE ratio of 27.96, a P/E/G ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 1-year low of $10.20 and a 1-year high of $18.80. The business has a 50-day moving average of $11.71 and a 200 day moving average of $13.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Commerce Bank raised its position in shares of Elanco Animal Health by 2.2% in the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after acquiring an additional 741 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in shares of Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company’s stock worth $524,000 after acquiring an additional 900 shares in the last quarter. Arizona State Retirement System raised its position in shares of Elanco Animal Health by 0.8% in the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company’s stock worth $1,737,000 after acquiring an additional 1,166 shares in the last quarter. MTM Investment Management LLC raised its position in shares of Elanco Animal Health by 9.3% in the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock worth $172,000 after acquiring an additional 1,200 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Elanco Animal Health by 5.9% in the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after acquiring an additional 1,464 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.